Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis.
Arthritis, Psoriatic
/ immunology
CD4 Antigens
/ drug effects
CD4-Positive T-Lymphocytes
/ drug effects
CD8 Antigens
/ drug effects
Cell Culture Techniques
Flow Cytometry
Humans
Interferon-gamma
/ drug effects
Interleukin-17
/ immunology
Phosphodiesterase 4 Inhibitors
/ pharmacology
Severity of Illness Index
Synovial Membrane
/ cytology
T-Lymphocyte Subsets
/ drug effects
Th1 Cells
/ drug effects
Th17 Cells
/ drug effects
Tumor Necrosis Factor-alpha
/ immunology
polyfunctional t-cells
psoriatic arthritis
synovial tissue
Journal
Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
18
07
2018
revised:
29
11
2018
accepted:
18
12
2018
pubmed:
11
1
2019
medline:
4
12
2019
entrez:
11
1
2019
Statut:
ppublish
Résumé
This study examines polyfunctional T-cells in psoriatic arthritis (PsA) synovial tissue and their associations with clinical disease and implications for therapy. PsA synovial tissue was enzymatically/mechanically digested to generate synovial tissue single cell suspensions. Frequencies of polyfunctional CD4, CD8, T-helper 1 (Th1), Th17 and exTh17 cells, using CD161 as a marker of Th17 plasticity, were determined by flow cytometry in matched PsA synovial tissue and peripheral blood. Synovial T-cell polyfunctionality was assessed in relation to Disease Activity in PSoriatic Arthritis (DAPSA) and in synovial cell suspensions cultured with a current mode of treatment, phosphodiesterase 4 (PDE4) inhibitor. PsA synovial tissue infiltrating CD4 These data demonstrate enrichment of polyfunctional T-cells in PsA synovial tissue which were strongly associated with DAPSA and ex vivo therapeutic response.
Identifiants
pubmed: 30626658
pii: annrheumdis-2018-214138
doi: 10.1136/annrheumdis-2018-214138
pmc: PMC6390025
doi:
Substances chimiques
CD4 Antigens
0
CD8 Antigens
0
IL17A protein, human
0
Interleukin-17
0
Phosphodiesterase 4 Inhibitors
0
Tumor Necrosis Factor-alpha
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-354Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Ann Rheum Dis. 2017 Sep;76(9):1550-1558
pubmed: 28473423
Front Immunol. 2018 Apr 04;9:606
pubmed: 29670615
Br J Rheumatol. 1994 Feb;33(2):133-8
pubmed: 8162477
Curr Opin Rheumatol. 2016 Jul;28(4):359-67
pubmed: 27152702
Arthritis Rheumatol. 2014 May;66(5):1272-81
pubmed: 24470327
PLoS One. 2015 Jun 05;10(6):e0128714
pubmed: 26046523
Arthritis Rheumatol. 2018 Jun;70(6):855-867
pubmed: 29439292
Cytokine. 2010 Jan;49(1):24-9
pubmed: 19942450
J Clin Invest. 2009 Mar;119(3):565-72
pubmed: 19188681
Curr Rheumatol Rep. 2011 Aug;13(4):353-9
pubmed: 21503693
J Exp Med. 2008 Aug 4;205(8):1903-16
pubmed: 18663128
Mol Cell Biochem. 2012 Jan;359(1-2):419-29
pubmed: 21894442
Lancet. 2015 Sep 19;386(9999):1137-46
pubmed: 26135703
J Immunol. 2004 Feb 1;172(3):1935-44
pubmed: 14734779
Clin Exp Rheumatol. 2018 May-Jun;36(3):486-489
pubmed: 29148410
J Virol. 2007 Aug;81(16):8468-76
pubmed: 17553885
Nat Commun. 2017 Nov 15;8(1):1510
pubmed: 29142230
J Immunol. 2001 Feb 15;166(4):2878-86
pubmed: 11160357
J Immunol. 2017 Mar 15;198(6):2249-2259
pubmed: 28167631
Clin Rheumatol. 2017 Feb;36(2):391-399
pubmed: 27995384
J Immunol Res. 2015;2015:906349
pubmed: 25973439
Cell Res. 2014 Dec;24(12):1387-402
pubmed: 25412660
Clin Rheumatol. 2015 Sep;34(9):1571-80
pubmed: 26152611